Boehringer/Zealand Dual Agonist Achieves Promising Level Of Weight Loss

Drug Targets GLP-1 And Glucagon Receptors

Jeans with a tape measure as a belt
Survodutide Achieved Up To 18.7% Weight Loss At 46 Weeks • Source: Shutterstock

More from Clinical Trials

More from R&D